Lead Product(s): Bispecific antibodies
Therapeutic Area: Genetic Disease
Highest Development Status: Discovery Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 13, 2020
The milestone was achieved upon the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific antibodies with approval to advance to IND-enabling studies.